TWI763802B - 眼用藥用組合物 - Google Patents

眼用藥用組合物

Info

Publication number
TWI763802B
TWI763802B TW107109677A TW107109677A TWI763802B TW I763802 B TWI763802 B TW I763802B TW 107109677 A TW107109677 A TW 107109677A TW 107109677 A TW107109677 A TW 107109677A TW I763802 B TWI763802 B TW I763802B
Authority
TW
Taiwan
Prior art keywords
aflibercept
polyoxyethylene
ophthalmic composition
formulations
ophthalmic
Prior art date
Application number
TW107109677A
Other languages
English (en)
Chinese (zh)
Other versions
TW201838646A (zh
Inventor
林光津
河秉緝
朴娜院
朴鎔涉
Original Assignee
南韓商參天堂製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商參天堂製藥股份有限公司 filed Critical 南韓商參天堂製藥股份有限公司
Publication of TW201838646A publication Critical patent/TW201838646A/zh
Application granted granted Critical
Publication of TWI763802B publication Critical patent/TWI763802B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
TW107109677A 2017-04-26 2018-03-21 眼用藥用組合物 TWI763802B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20170053782 2017-04-26
??10-2017-0053782 2017-04-26
KR10-2017-0053782 2017-04-26
KR10-2017-0120262 2017-09-19
??10-2017-0120262 2017-09-19
KR1020170120262A KR101861163B1 (ko) 2017-04-26 2017-09-19 안과용 약학 조성물

Publications (2)

Publication Number Publication Date
TW201838646A TW201838646A (zh) 2018-11-01
TWI763802B true TWI763802B (zh) 2022-05-11

Family

ID=62299585

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107109677A TWI763802B (zh) 2017-04-26 2018-03-21 眼用藥用組合物

Country Status (9)

Country Link
US (1) US10646546B2 (fr)
EP (1) EP3452075B1 (fr)
JP (1) JP6677827B2 (fr)
KR (1) KR101861163B1 (fr)
CN (1) CN109475597B (fr)
ES (1) ES2902325T3 (fr)
PL (1) PL3452075T3 (fr)
TW (1) TWI763802B (fr)
WO (1) WO2018199408A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
EP3709971A2 (fr) * 2017-11-17 2020-09-23 Amgen Inc. Formulations de protéines de fusion vegfr-fc
WO2019217927A1 (fr) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
US20220054586A1 (en) * 2018-09-10 2022-02-24 Samsung Bioepis Co., Ltd. Liquid composition comprising protein
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN114206924A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
KR20210077645A (ko) * 2019-12-17 2021-06-25 주식회사 프로젠 신규 주사제 제형
JP2023535933A (ja) * 2020-07-24 2023-08-22 パンジェン バイオテック インコーポレイテッド 眼科用液状組成物
KR20230131212A (ko) * 2021-01-14 2023-09-12 한올바이오파마주식회사 안정화제를 사용하지 않고도 안정한, 탄파너셉트를포함하는 안과용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208989A1 (fr) * 2015-06-23 2016-12-29 Alteogen, Inc. Formule liquide stable d'une protéine de fusion présentant un domaine fc d'igg

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029103A2 (fr) 2006-06-16 2009-03-04 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriées à une administration intravitréenne
EP2248517B1 (fr) * 2009-05-08 2014-03-26 PARI Pharma GmbH Formules pharmaceutiques à stabilisation de membrane concentrée
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2013181495A2 (fr) * 2012-06-01 2013-12-05 Ophthotech Corporation Compositions comprenant un aptamère anti-pdgf et un antagoniste de vegf
TW201605468A (zh) * 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑
AR102494A1 (es) * 2014-11-07 2017-03-01 Novartis Ag Métodos para tratar enfermedades oculares
CN105496955A (zh) * 2015-12-11 2016-04-20 北京蓝丹医药科技有限公司 一种二氟泼尼酯眼用乳剂及其制备方法
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
MA50174A (fr) * 2017-09-18 2020-07-29 Amgen Inc Formules de protéines de fusion vegfr-fc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208989A1 (fr) * 2015-06-23 2016-12-29 Alteogen, Inc. Formule liquide stable d'une protéine de fusion présentant un domaine fc d'igg

Also Published As

Publication number Publication date
EP3452075B1 (fr) 2021-11-24
EP3452075A4 (fr) 2019-12-11
CN109475597B (zh) 2022-03-22
WO2018199408A1 (fr) 2018-11-01
KR101861163B1 (ko) 2018-05-25
US20190160145A1 (en) 2019-05-30
JP2019517513A (ja) 2019-06-24
JP6677827B2 (ja) 2020-04-08
CN109475597A (zh) 2019-03-15
ES2902325T3 (es) 2022-03-28
EP3452075A1 (fr) 2019-03-13
PL3452075T3 (pl) 2022-02-21
TW201838646A (zh) 2018-11-01
US10646546B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
TWI763802B (zh) 眼用藥用組合物
JP6667519B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
AU2013211645B2 (en) Stabilised protein compositions based on semifluorinated alkanes
JP5458188B2 (ja) 抗ｃｄ４０抗体の高濃度製剤
ES2881671T3 (es) Formulaciones de liposomas
KR20160135372A (ko) 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
EA034839B1 (ru) Офтальмологический раствор
US20220370364A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
WO2023281367A1 (fr) Formulations liquides stables d'aflibercept
RU2817350C2 (ru) Липосомальные препараты
TW202404651A (zh) 用於脈絡膜上投與之調配物諸如形成聚集體之調配物